12 August 2025 IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced it has signed two separate new commercial contracts to provide neuroimaging services across different core therapeutic indications. The combined value of the new contracts is circa £1.3 million.

Under the first contract IXICO will provide trial management and imaging analysis for a Phase 1 Alzheimer’s Disease (AD) clinical trial by a major pharmaceutical company. The contract scope covers a collaboration for approximately three and a half years.

The second contract with a US-based biotech sees IXICO facilitating high quality imaging data collection for a Phase 1b trial to aid surgical planning in Friedrich’s Ataxia (FA), a progressive inherited neurodegenerative disorder that effects the nervous system and heart. The contract scope covers a collaboration for six years.

This positive commercial momentum continues IXICO's successful execution of its 'Innovate, Lead, Scale' strategy to drive global expansion and growth.

Bram Goorden, CEO of IXICO, commented: "The contract wins underline the innovative, adaptable and agile nature of the IXICO platform and our teams as irrefutable thought leaders in the neurodegenerative disease space. The two deals hit different key elements of our strategy, respectively supporting Alzheimer’s as a core indication, and; maintaining our leadership position in the rare CNS disease space.”

For further information please contact:

IXICO plc	+44 (0) 20 3763 7499
Grant Nash, Chief Financial Officer James Chandler, Chief Business Officer	info@ixico.com
Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker)	+44 (0) 20 7220 0500
Giles Balleny (Corporate Finance) Nigel Birks (Healthcare Specialist Sales) Harriet Ward (Corporate Broking) Michael F Johnson (Sales)

---